Related Experiment Videos

Mendelian Randomization Study on the Associations Between Genetically Predicted Cardiovascular Disease Subtypes and

Qiaolin Tang1, Xiangzhu Meng1, Xiaowen Tu1

  • 1Department of Cardiology, Jiangxi Province Hospital of Integrated Chinese and Western Medicine, Nanchang, China.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|March 28, 2025
PubMed

Insights

Cardiovascular diseases like heart failure, hypertension, and atrial fibrillation increase the risk of dilated cardiomyopathy. Genetic links to hypertrophic cardiomyopathy were not found. Effective management of these conditions is crucial for prevention.

Area of Science:

  • Cardiovascular Genetics
  • Epidemiology
  • Internal Medicine

Background:

  • Cardiomyopathies are often presumed to have genetic roots, but their relationship with cardiovascular diseases (CVD) requires further clarification.
  • Understanding causal links between CVD subtypes and cardiomyopathies is essential for effective prevention strategies.

Purpose of the Study:

  • To investigate the potential causal relationships between genetically predicted cardiovascular disease subtypes and the risk of developing dilated and hypertrophic cardiomyopathies using Mendelian randomization.
  • To identify specific CVDs that may predispose individuals to cardiomyopathies within a European population.

Main Methods:

  • A Mendelian randomization (MR) approach was utilized, analyzing summary-level data from genome-wide association studies.
  • Primary analysis employed random-effects inverse-variance weighting, with sensitivity analyses including weighted median, MR-Egger, and multivariable MR methods.

Main Results:

  • A genetic predisposition to atrial fibrillation (OR: 1.33), heart failure (OR: 3.22), and hypertension (OR: 1.50) was causally associated with an increased risk of dilated cardiomyopathy.
  • No significant causal links were found between genetically predicted coronary heart disease, pulmonary embolism, ischemic stroke, or any CVD subtypes and hypertrophic cardiomyopathy.
  • Heart failure showed a significant association with dilated cardiomyopathy risk.

Conclusions:

  • Genetically predicted heart failure, hypertension, and atrial fibrillation are significant risk factors for dilated cardiomyopathy.
  • No genetic predisposition to CVD subtypes was found to cause hypertrophic cardiomyopathy.
  • These findings emphasize the importance of managing heart failure, hypertension, and atrial fibrillation for preventing dilated cardiomyopathy.

Keywords:
cardiovascular disease subtypesdilated cardiomyopathyhypertrophic cardiomyopathyischemic strokemendelian randomizationpulmonary embolism

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...